Rathi Srinivas

Rathi Srinivas has a diverse range of work experience. From 2008 to 2009, Rathi participated in Merck's Future Talent Summer Program. In 2009, they began their PhD research in Chemical Engineering with a minor in Biotechnology at the Massachusetts Institute of Technology (MIT). During their time at MIT, they conducted research under the supervision of Professor Patrick Doyle, focusing on developing hydrogel-based bioassays using microfluidic technologies. In addition, Rathi served as a Teaching Assistant for a polymer science laboratory course.

Following their time at MIT, Rathi co-founded Novopyxis in 2014. As a co-founder, they played a crucial role in the development of therapeutics and medical devices, including a flagship drug that has demonstrated cardioprotective and neuroprotective properties.

In 2017, Rathi founded Droplette and assumed the role of Chief Technology Officer (CTO). The specific responsibilities and accomplishments related to this position are not provided.

Throughout their career, Rathi has also worked at Firefly Bioworks as a Researcher, contributing to the development of signal amplification assays for a commercial microRNA hydrogel-particle kit. They also spent time as a Research Assistant in the Gonzalez Research Group at Columbia University in the City of New York.

Furthermore, Rathi has been recognized for their contributions and innovative ideas. In 2014, they were an Innovation Cup Finalist at Merck Serono.

Rathi Srinivas completed their high school education at Manalapan HS, although the specific years are not provided. They then attended Columbia University from 2005 to 2009 and obtained a Bachelor of Science degree in Chemical Engineering. Following this, Rathi pursued further education at the Massachusetts Institute of Technology where they earned a PhD in Chemical Engineering from 2009 to 2015.